rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KZIA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards

      Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, has been named "Drug Discovery Company of the Year" in the 2026 BioTech Breakthrough Awards program, recognizing the Company's innovative approach to developing next-generation cancer therapeutics.

      Nov 5Yahoo FinanceKZIA
      Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
      Nov 2Yahoo FinanceKZIA
      This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
      Oct 30BenzingaKZIA
      Kazia stock gains as Guggenheim starts at Buy (KZIA:NASDAQ)
      Oct 21Seeking AlphaKZIA
      Guggenheim initiates Kazia Therapeutics stock with buy rating
      Oct 21Investing.comKZIA
      Why is Kazia Therapeutics stock rallying today?
      Oct 20Investing.comKZIA
      Leerink initiates Kazia Therapeutics stock with $30 target
      Oct 20Investing.comKZIA
      Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial

      Detailed price information for Kazia Therapeutics Ltd ADR (KZIA-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailKZIA
      Kazia receives $2m milestone as paxalisib epilepsy trial starts
      Sep 22Investing.comKZIA
      Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq

      Detailed price information for Kazia Therapeutics Ltd ADR (KZIA-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailKZIA
      Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer - Slideshow (NASDAQ:KZIA) 2026-09-11
      Sep 11Seeking AlphaKZIA
      Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

      Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib in combination with gemcitabine for patients ages 1 to 39 with recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT). AT/RT is w

      Sep 9Yahoo FinanceKZIA
      Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?

      Kazia Therapeutics Limited (NASDAQ:KZIA) has materially strengthened its financing position, but the clinical case for expanding paxalisib into HR-positive, HER2-negative metastatic breast cancer remains at the preclinical stage. Paxalisib is an investigational, brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway. On August 31, Kazia Therapeutics Limited (NASDAQ:KZIA) closed a registered public offering that Kazia Therapeutics Limited (NASDAQ:KZIA) […]

      Sep 9Yahoo FinanceKZIA
      Exclusive BAC Article: Kazia Therapeutics; Positive Phase 1 TNBC Data, Interim Combination Data 2026/2027, HR+/HER2- BC Expansion, And Catalysts (NASDAQ:KZIA)
      Sep 1Seeking AlphaKZIA
      BTIG raises Kazia Therapeutics stock price target on trial data
      Sep 1Investing.comKZIA
      Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

      Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical and translational data showing that its lead asset, paxalisib, reduced tumor burden, the total amount of cancer in the body, by 52% (p=0.035) in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer. In a separate study, adding

      Sep 1Yahoo FinanceKZIA
      Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

      Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, including evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors to standard-of-care therapy. Based on these findings,

      Sep 1Yahoo FinanceKZIA
      Kazia closes oversubscribed offering to fund paxalisib’s clinical development

      Paxalisib is being studied in various cancers and has received several regulatory designations from the FDA.

      Sep 1Yahoo FinanceKZIA
      Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study

      Kazia Therapeutics (KZIA) said Tuesday that data showed its paxalisib therapy significantly reduced

      Sep 1Yahoo FinanceKZIA
      Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

      Newswire.ca Press Release.

      Aug 31The Globe and MailKZIA
      Kazia Therapeutics: Worth Speculating On Paxalisib’s TNBC Data (NASDAQ:KZIA)

      Kazia’s first 6 TNBC patients all achieved clinical benefits. These early results make paxalisib a much more promising asset going forward.

      Aug 31Seeking AlphaKZIA
      Kazia Therapeutics stock falls on $40M public offering
      Aug 28Investing.comKZIA
      Kazia Therapeutics prices $40 million public offering
      Aug 28Investing.comKZIA
      Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

      Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in

      Aug 28Yahoo FinanceKZIA
      Kazia Therapeutics launches public offering of ADSs and warrants
      Aug 27Investing.comKZIA
      Kazia reports clinical benefit in six breast cancer patients
      Aug 27Investing.comKZIA
      Kazia Therapeutics Limited Announces Proposed Public Offering

      Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the "Offering") of (i) American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain i

      Aug 27Yahoo FinanceKZIA
      Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

      Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer (TNBC). Five of the six patients achieved an objective response – a measurable 30% or greater

      Aug 27Yahoo FinanceKZIA
      Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib (NASDAQ:KZIA)

      Kazia Therapeutics' pipeline is validated by recent PI3K/AKT/mTOR pathway approvals and acquisitions.. Read more on KZIA stock here.

      Aug 27Seeking AlphaKZIA
      Kazia Therapeutics Achieves 100% Clinical Benefit Rate in Initial Patients for Advanced Triple-Negative Breast Cancer

      Kazia Therapeutics (KZIA) said late Thursday new data for its lead asset, paxalisib, achieved a 100%

      Aug 27Yahoo FinanceKZIA
      Kazia Therapeutics Proposes Tranched Public Offering

      Kazia Therapeutics (KZIA) said late Thursday it has commenced a tranched registered public offering

      Aug 27Yahoo FinanceKZIA

      This is the newest page. Registered accounts read further back.